This database contains 38 studies, archived under the term: "parkinson disease"
Click here to filter this large number of results.
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]
Altered microstructure in corticospinal tract in idiopathic normal pressure hydrocephalus: comparison with Alzheimer disease and Parkinson disease with dementia
Hattori, T.,
Yuasa, T.,
Aoki, S.,
Sato, R.,
Sawaura, H.,
Mori, T.,
Mizusawa, H.
Background and Purpose: Previous neuropathologic studies in chronic hydrocephalus have suggested the presence of white matter damage, presumably from mechanical pressure due to ventricular enlargement and metabolic derangement. This study aimed to investigate the diffusional properties of the CST in patients with iNPH by using DTI and to determine whether this method could be used […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]
The mini-mental Parkinson’s (MMP) as a cognitive screening tool in people with Parkinson’s disease
Caslake, Robert,
Summers, Fiona,
McConachie, Douglas,
Ferris, Catriona,
Gordon, Joanna,
Harris, Clare,
Caie, Linda,
Counsell, Carl
Background: Cognitive decline is common in Parkinson’s disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer’s disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English […]
What predicts cognitive decline in de novo Parkinson’s disease?
Arnaldi, Dario,
Campus, Claudio,
Ferrara, Michela,
Famà, Francesco,
Picco, Agnese,
De Carli, Fabrizio,
Accardo, Jennifer,
Brugnolo, Andrea,
Sambuceti, Gianmario,
Morbelli, Silvia,
Nobili, Flavio
Subtle cognitive impairment can be detected in early Parkinson’s disease (PD). In a consecutive series of de novo, drug-naive PD patients, we applied stepwise regression analysis to assess which clinical, neuropsychological, and functional neuroimaging (dopamine transporter [DAT] and perfusion single photon emission computed tomography [SPECT]) characteristics at baseline was predictive of cognitive decline during an […]
Neuropsychological assessment of driving safety risk in older adults with and without neurologic disease
Anderson, Steven W.,
Aksan, Nazan,
Dawson, Jeffrey D.,
Uc, Ergun Y.,
Johnson, Amy M.,
Rizzo, Matthew
Decline in cognitive abilities can be an important contributor to the driving problems encountered by older adults, and neuropsychological assessment may provide a practical approach to evaluating this aspect of driving safety risk. The purpose of the present study was to evaluate several commonly used neuropsychological tests in the assessment of driving safety risk in […]
Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
Aarsland, Dag,
Ballard, Clive,
Walker, Zuzana,
Bostrom, Fredrik,
Alves, Guido,
Kossakowski, Katja,
Leroi, Iracema,
Pozo-Rodriguez, Francisco,
Minthon, Lennart,
Londos, Elisabet
Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine […]